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Human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 is targeted by broadly-reactive neutralizing antibodies 2F5
and 4E10, making it an attractive target for vaccine development. To better assess immunogenic properties of gp41, we generated five soluble
glutathione S-transferase fusion proteins encompassing C-terminal 30, 64, 100, 142, or 172 (full-length) amino acids of gp41 ectodomain from M
group consensus envelope sequence. Antibody responses in HIV-1-infected patients were evaluated using these proteins and overlapping peptides.
We found (i) antibody responses against different regions of gp41 varied tremendously among individual patients, (ii) patients with stronger
antibody responses against membrane-proximal external region exhibit broader and more potent neutralizing activity, and (iii) several patients
mounted antibodies against epitopes that are near, or overlap with, those targeted by 2F5 or 4E10. These soluble gp41 fusion proteins could be an
important source of antigens for future vaccine development efforts.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; gp41; Neutralizing antibody; MPERIntroduction
During human immunodeficiency virus type 1 (HIV-1) in-
fection, many antibodies are elicited against viral envelope
glycoprotein. The vast majority of these antibodies are non-
neutralizing, and those that neutralize are mostly isolate-specific
(for reviews, see (Burton et al., 2005; Poignard et al., 2001)).
Results from both active and passive immunization studies
indicate that pre-existing neutralizing antibodies (Nabs) can
confer protection against HIV-1 infection (Baba et al., 2000;
Cho et al., 2001; Conley et al., 1996; Mascola et al., 2000;⁎ Corresponding author. Case Western Reserve University School of
Medicine, Department of Medicine, Division of Infectious Diseases, 10900
Euclid Avenue, Cleveland, OH 44106-4984, USA. Fax: +1 216 368 0069.
E-mail address: mcho@case.edu (M.W. Cho).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.11.009Parren et al., 1995; Shibata et al., 1999; Trkola et al., 2005).
However, the precise role of humoral immunity in controlling
natural HIV-1 infection is not yet clear. Better understanding of
antibody responses against HIV-1 envelope glycoproteins in
virus-infected patients may facilitate development of a pro-
tective vaccine against the virus.
Antisera that exhibit broadly neutralizing activity against
diverse HIV-1 isolates have been observed in some long-term
non-progressors (LTNP) (Braibant et al., 2006; Cecilia et al.,
1999; Pilgrim et al., 1997). However, they are rare; despite over
two decades of AIDS research, only a handful of broadly re-
active Nabs (BR-Nabs) have been identified, including mono-
clonal antibodies (mAbs) b12, 2G12, 447-52D, 2F5, 4E10 and
m48 (Gorny et al., 1992; Muster et al., 1993; Roben et al., 1994;
Stiegler et al., 2001; Trkola et al., 1996; Zhang et al., 2006;
Zwick et al., 2001). While the first three antibodies are gp120-
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are of great interest from a vaccine development standpoint
because they are more cross-reactive against viruses from dif-
ferent clades than those directed against gp120 (Binley et al.,
2004; Burton et al., 2004; Opalka et al., 2004; Yuste et al., 2006;
Zwick et al., 2001).
Monoclonal antibodies 2F5 and 4E10 target adjacent, but
distinct, linear epitopes in a highly conserved region of gp41
near the viral membrane known as the membrane-proximal
external region (MPER) (Muster et al., 1993; Stiegler et al.,
2001; Zhang et al., 2006; Zwick et al., 2001), a determinant that
plays a critical role in HIV-1 fusion with the cell membrane
(Salzwedel et al., 1999; Suarez et al., 2000). Epitope mapping
studies of 2F5 with synthetic peptides (Barbato et al., 2003;
Biron et al., 2002; Joyce et al., 2002), phage displayed peptide
libraries (Menendez et al., 2004; Muster et al., 1993; Zwick
et al., 2001), and protease protection assays (Parker et al., 2001)
have identified ELDKWA as the core antibody binding site.
4E10 binds primarily to the hexapeptide NWFNIT, which lies
just four amino acids downstream of the 2F5 epitope (Brunel
et al., 2006; Cardoso et al., 2005; Stiegler et al., 2001; Zwick
et al., 2001). The epitope for m48 has not yet been precisely
defined although it is thought to be distinct from those rec-
ognized by 2F5 or 4E10, and highly conformational, requiring
proper disulfide bond formation (Zhang et al., 2006).
During the past two decades, much of HIV-1 vaccine devel-
opment efforts have focused on gp120. Consequently, much
less is known about the immunological properties of gp41.
Efforts to evaluate immunogenicity of gp41 have been ham-
pered by the fact that the protein, either as a whole or in part, is
difficult to express in soluble forms in the absence of gp120
(Gairin et al., 1991; Luo et al., 2006; Qiao et al., 2005; Scholz
et al., 2005; Weissenhorn et al., 1997a). Moreover, the large
number of highly immunogenic epitopes on gp120 renders
gp160 or gp140 unsuitable for assessing immunogenic proper-
ties of gp41, particularly against the MPER (Pantophlet and
Burton, 2003; Wei et al., 2003). In addition, assessment of
antibody responses against gp41 in virus-infected patients has
been done mostly in the context of short, synthetic peptides
(Calarota et al., 1996; Gnann et al., 1987; Goudsmit et al., 1990;
Horal et al., 1991; Schrier et al., 1988). While peptides are
suitable for identifying linear epitopes, antibody responses to
non-contiguous, conformational epitopes cannot be assessed.
To date, most efforts to express soluble forms of gp41 have
been limited to small fragments of the protein, including the heptad
repeat (HR) regions (Root et al., 2001), the immunodominant loop
between HR1 and HR2 known as cluster I (Gnann et al., 1987), a
region between HR2 and the 2F5 epitope known as cluster II
(Binley et al., 1996;Goudsmit et al., 1990;Xu et al., 1991), and the
MPER (Luo et al., 2006; Opalka et al., 2004). Although Scholz
et al. (Scholz et al., 2005) have reported generating a larger 146
amino acid gp41 fragment (residues 536–681) fused to E. coli
chaperone SlyD and showed its immunoreactivity with HIV-1
patient sera, no other immunoprobing was performed using mAbs
to confirm antigenic integrity of the protein.
In this study, we systematically generated five glutathione
S-transferase (GST)-fusion proteins, which consist of C-terminal30, 64, 100, 142, or 172 (full-length) amino acid residues of the
gp41 ectodomain from anM group consensus envelope sequence
(MCON6). They were expressed in E. coli, solubilized and puri-
fied. These proteins, in conjunction with consensus overlapping
peptides, were used to evaluate antibody responses against gp41
in HIV-1-infected patients.
Results
Design, expression and purification of GST-gp41 fusion proteins
To assess antibody responses against conformational, non-
contiguous epitopes on gp41 in HIV-1-infected patients, we
constructed five gp41 fragments fused to glutathione-S-transfer-
ase (GST). GSTwas chosen as a fusion partner to facilitate protein
refolding process. Proteins are truncated N-terminally, each about
30–40 amino acids apart, containing the C-terminal 30, 64, 100,
142, or the entire 172 a.a. of the protein (Fig. 1A). Therefore, each
is designed to encompass the MPER containing the epitopes
recognized by mAbs 2F5 and 4E10. The truncation sites were
chosen to be either just up- or down-stream of HR domains. In
addition, sites were chosen so that the N-terminal ends of the gp41
fragments would be charged amino acids (i.e. RQ for -142, ER for
-100, DE for -64, and EK for -30). Proteins were tagged with six-
histidine residues at the C-terminus to facilitate protein renatura-
tion and purification. In order to enhance protein recognition by
antisera from patients infected with a wide range of primary
isolates from different clades, we chose to generate our gp41
fragments from an envelope from the M group consensus
sequence (MCON6).
All five fusion proteins were expressed efficiently in E. coli
BL21(DE3) upon induction with IPTG (Figs. 1B and C). As
expected, all five proteins were insoluble. Anticipating diffi-
culty in solubilizing two larger gp41 fragments, our initial
efforts focused on GST-gp41-30, -64 and -100. Bacterial pellets
were sonicated, and inclusion bodies were isolated and de-
natured in 8 M urea. Solubilized proteins were bound to Ni-
NTA resin. Subsequently, proteins were renatured gradually by
sequential incubation with decreasing concentrations of urea
(8 M, 6 M, 4 M, 3 M, 2 M and 1 M) before a final wash with
PBS and elution from the resin using imidazole. Eluted proteins
were finally dialyzed in PBS. This single-step purification/
renaturation procedure yields about 37, 40, and 20 mg per liter
for GST-gp41-30, -64, and -100, respectively, with N85–90%
purity (Fig. 2A). The identities of the purified proteins were
confirmed by Western immunoblot using anti-GST antibody
(Fig. 2B). Aminor band of unknown identity (∼23 kDa) was co-
purified with GST-gp41-64 (Fig. 2A). The contaminant is likely
a cleavage product of GST since it is immunoreactive to anti-
GST-antibody (Fig. 2B). To verify that our fusion proteins are
antigenically correct, they were subjected to immunoprecipita-
tion analyses using BR-Nabs 2F5 and 4E10, followed by
Western immunoblot with anti-GST antibody. As shown in
Figs. 2C and D, all three proteins were recognized by 2F5
and 4E10, respectively. Recognition of GST-gp41-30 by 4E10,
however, appeared somewhat weaker than that seen against
GST-gp41-64 and -100. No binding was observed for GST
Fig. 1. Construction and expression of GST-gp41 fusion proteins. (A) A schematic diagram of gp41 and the five GST-gp41 fusion proteins generated. Key features of
gp41 are indicated. Linear B cell epitopes identified to date are shown above gp41, and 2F5 and 4E10 binding sites are indicated. FP=Fusion Peptide; HR=Heptad
Repeat; ID=Immunodominant region; TM=Transmembrane domain. (B and C) SDS-PAGE analyses of GST-gp41 fusion protein expression in uninduced (U) and
induced (I) E. coli cells. Arrows indicate GST-gp41 fusion proteins. Gels were stained with Coomassie Blue. (D) Sequence of MCON6 gp41 ectodomain with 6x-His
tag. The starting residues of each construct are indicated by an inverted triangle.
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2F5 and 4E10.
Having successfully generated soluble GST-gp41-30, -64,
and -100, we pursued generating soluble GST-gp41-142 and
-172. Solubilization of the two larger proteins was more diffi-
cult. Initially, we followed the same protocol used to solubilize
the smaller proteins. However, this resulted in precipitation of
the proteins even at 6 M urea. We hypothesized that a slower
transition from 8 M to 6 M should provide more time needed for
the protein to refold into the conformation that would render
the protein soluble. Using a continuous, shallow gradient (see
Materials and methods for details), we were able to maintain a
significant portion of the protein soluble (Fig. 2E). Typical final
yields for GST-gp41-142 and -172 were about 5.4 and 4.5 mg/l,Fig. 2. Purification and immunoprecipitation analyses of GST-gp41 fusion proteins
purified. Proteins were analyzed by silver stain (A), Western blot with anti-GSTantibo
blot with anti-GST antibody. (E) Coomassie Blue-stained SDS-PAGE analyses of prespectively, which are significantly lower than for the smaller
fusion proteins, but sufficient for our studies. In addition to the
difficulty in solubilizing these proteins, we observed that these
proteins would precipitate upon repeated freezing-and-thawing.
To prevent protein precipitation, working stocks of the proteins
were kept at near 0 °C (ice bath) in a cold room.
Characterization of antigenic properties of GST-gp41 fragments
ELISAwas performed to evaluate the antigenic properties of
purified gp41 fusion proteins more quantitatively. Proteins were
probed with BR-Nabs 2F5 and 4E10, polyclonal HIV-Ig (from
pooled HIV-1 patient sera), and mAb 98-6, which recognizes
the coiled-coil structure of the HR1 and HR2 regions (5-helix or. GST and three gp41 variants (-30, -64 and -100) were initially expressed and
dy (B), and immunoprecipitation with 2F5 (C) or 4E10 (D) followed byWestern
urified GST-gp41-142 and -172.
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Wells were coated with equimolar amounts of the proteins to
assess relative antigenicity.
2F5 was similarly reactive against all five gp41 protein frag-
ments, indicating that the epitope recognized by the antibody is
conformationally similar and equally exposed among all five
proteins (Fig. 3A). In contrast, some variations in recognition of
the proteins by 4E10 were observed despite the fact that all
proteins contain the same epitope recognized by the antibody
(Fig. 3B). Compared to GST-gp41-64, -142, and -172, which
were equally reactive, GST-gp41-30 and -100 were about 20- and
5-fold less reactive, respectively. This was somewhat surprising
considering that the 4E10 binding site is only 4 amino acids
downstream of 2F5 epitope. In addition, 4E10 binding strength
was significantly weaker against the five proteins compared with
2F5, requiring approximately 5 to 100 fold higher concentrations
(Fig. 3B). This was not unexpected since 4E10 exhibits relatively
weak, albeit broad, neutralizing activity (Binley et al., 2004).
98-6 reacted strongly against GST-gp41-142 and -172,
indicating that these proteins exist in post-hairpin formation
configuration (Fig. 3C). As predicted, the three smaller proteins
were not detected by 98-6 since they do not contain both heptad
repeat regions required to form the coiled-coil structure. Similar
to 98-6, HIV-Ig reacted most strongly against GST-gp41-172
and -142 (Fig. 3D). Although GST-gp41-100, -64 and -30
fusion proteins were significantly less reactive with HIV-Ig
compared to -172 and -142, antibodies against them could be
detected using higher concentrations of the antibody and longer
enzymatic reaction time (Fig. 3E). Among the three smallerFig. 3. Characterization of antigenic properties of GST-gp41 fusion proteins. Purified
(A), 4E10 (B), 98-6 (C) and polyclonal HIV-Ig (D and E). Equimolar amounts (0.5 pm
smaller fusion proteins by HIV-Ig, higher concentrations of the antibody were usedproteins, HIV-Ig reacted most strongly against GST-gp41-100,
which was expected since it contains the immunodominant
domain of gp41 (Fig. 1A). GST-gp41-64 was also reactive,
albeit less than GST-gp41-100. In contrast, GST-gp41-30 re-
acted very weakly, supporting the notion that the MPER is
poorly immunogenic in the context of natural HIV-1 infection.
Characterization of antibody responses against gp41 in
HIV-1-infected patients
Evaluating antibody responses against HIV-1 envelope gly-
coproteins using HIV-Ig provides only an overall picture be-
cause antibodies are prepared from a large number of virus-
infected patient sera. We hypothesized that we might see some
differences amongst individual patients considering significant
polymorphism in the host immune system and/or variation in
viral genome. The results from studies described above demon-
strated that the soluble GST-fusion proteins we generated are
antigenically intact and suitable for assessing immune responses
against gp41 in HIV-1-infected patients.
Since all of the epitopes targeted by BR-Nabs identified to
date map within the C-terminal 100 amino acids, we focused our
efforts on characterizing antibody responses against GST-gp41-
30, -64, and -100. Archived plasma samples from 44 HIV-1-
infected patients were evaluated by ELISA using equimolar
amounts of the three GST fusion proteins. Purified GST protein
was used as a negative control. Results are shown in Fig. 4.
Patient samples were arranged in descending order of magnitude
of antibody reactivity against GST-gp41-30 (numbered CWRU-GST and GST-gp41 fusion proteins were analyzed by ELISA using mAbs 2F5
ol) of GSTor GST-gp41 fusion proteins were coated in each well. To detect three
with extended enzymatic reaction time in panel (E).
Fig. 4. Antibody responses against gp41 in individual patients. (A) ELISA was performed with plasma samples from HIV-1-infected patients at a dilution factor of
1:300. Plasma from an uninfected individual (HIV-ve) and no plasma were used as controls. Plasma samples are arranged in descending order of reactivity to GST-
gp41-30. Six samples exhibiting the highest reactivity (●) and six samples with lower reactivity (⁎), which are further evaluated in Figs. 5 and 6, are indicated. Patients
who have been infected longer than 5 years with CD4 counts N500 and never been on anti-retroviral therapy are indicated by black bars on the top. For clarity, average
A450 value of GSTonly is shown as a line indicated as GST. Arrowheads indicate average A450 values against each fusion protein for all patients. Equimolar amounts
(0.5 pmol) of GSTor GST-gp41 fusion proteins were coated in each well. (B) Dot plot analyses of ELISA data showing distribution of antibody reactivity against each
fusion protein. Median values are shown.
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and -41) were on anti-retroviral therapy at the time when the
plasma samples were taken.
Overall, the strongest antibody responses were detected
using GST-gp41-100, followed by -64 and -30, consistent with
what we observed using HIV-Ig (Fig. 3E); the mean A450 val-
ues were 1.8, 1.3 and 0.4 (Fig. 4A), and the median values were
1.9, 1.0 and 0.3 (Fig. 4B), respectively. Interestingly, we ob-
served tremendous variation amongst individual patients in
antibody reactivity against our three gp41 fragments, both in
terms of the magnitude and binding pattern, as we hypothesized.
Some of the patients exhibited very low antibody titers against
all three gp41 fragments (e.g. CWRU-28, -34, -40 and -42),
whereas others mounted strong antibody responses against all of
them (e.g. CWRU-1, -3 and -5). While some patients showed
good binding against only the GST-gp41-100 (e.g. CWRU-22,
-25, -32, -36, -39, -43), other patients exhibited good reactivity
against both GST-gp41-100 and -64, but not -30 (e.g. CWRU-
29, -33, -35, -38). In general, antibody responses against GST-
gp41-64 were most variable with standard deviation of 0.98,
compared to 0.35 and 0.55 of GST-gp41-30 and -100, re-
spectively (Fig. 4B). Interestingly, markedly greater antibody
responses were observed against GST-gp41-64 than against
-100 in seven patients (CWRU-1, -3, -5, -8, -10, -13 and -17),
despite the fact that the latter protein is larger. One possibleexplanation is that immunogenic epitopes recognized on GST-
gp41-64 in these particular patients are buried in the context of
GST-gp41-100.
Perhaps the most intriguing aspect of this study was that there
were many patients who mounted strong antibody responses
against gp41MPER, three of them in particular, as demonstrated
by antibody reactivity to GST-gp41-30. Retrospective analyses
of the patients showed that many patients who might be
considered as “slow progressors” (infected longer than 5 years,
CD4 T-cell count N500, and never been on anti-retroviral
therapy; indicated by black bars on top of Fig. 4A) generally
exhibited higher antibody reactivity against GST-gp41-30. Pre-
vious studies have shown that BR-Nabs are stronger and more
frequent in LTNPs than other infected patients (Cecilia et al.,
1999; Pilgrim et al., 1997). This result raised a possibility that
some of these patients could have BR-Nabs targeting theMPER,
some of which could exhibit 2F5- or 4E10-like properties.
Antisera from HIV-1-infected patients with stronger reactivity
against gp41MPER exhibit broader andmore potent neutralizing
activity
To test our hypothesis that patients who mount stronger anti-
body responses against gp41-MPER might have broader neu-
tralizing activity, we compared neutralizing activity of antisera
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(CWRU-1 to -6) and six other patients with lower reactivity
(CWRU-19, -29, -36, -38, -41 and -43) indicated by dots and
asterisks in Fig. 4A, respectively. The latter samples were chosen
semi-randomly to make sure they had good antibody reactivity
against GST-gp41-100. Neutralization assays were performed
against four primary R5 or R5/X4 HIV-1 isolates (BAL, AD8,
DH12 and 89.6) using a single-round pseudovirus infection assay.
Viruses pseudotyped with vesicular stomatitis virus G protein
(VSV-G) were used as a negative control.
Although there was no absolute correlation between antibody
reactivity against GST-gp41-30 and breadth or potency of
neutralizing activity on an individual patient basis, overall, the
plasma from patients with higher reactivity did exhibit broader
and more potent activity (Fig. 5A; pb0.01). This was particularly
true for patients CWRU-3, -4 and -6. It is also noteworthy that
plasma samples from these patients efficiently neutralized HIV-
1AD8, which is one of the most difficult viruses to elicit neu-
tralizing antibodies against (Bower et al., 2006; Cho et al., 2001;
Kim et al., 2005, 2003); none of the six samples with lower GST-
gp41-30 reactivity exhibited strong neutralizing activity against
this virus. In contrast, plasma samples from all twelve patients
neutralized HIV-189.6 quite effectively, suggesting that this virus
might be particularly sensitive to neutralization despite being a
primary isolate. Titration analyses of plasma samples from six
patients with strong reactivity against GST-gp41-30 confirmed
potent neutralizing activity of those from patients CWRU-3, -4
and -6 (Fig. 5B). The analyses showed that patient CWRU-5 also
exhibited quite potent neutralizing activity against all viruses,
albeit somewhat less effectively against HIV-1AD8. None of theFig. 5. Neutralizing activity of patient plasma samples. HIV-1 Env pseudotyped viru
TZM-bl cell-based assay. Data are shown as a percentage of virus infectivity in the
reactivity to GST-gp41-30 were analyzed at a single plasma dilution factor of 1:90. MA
of the plasma samples neutralized VSV-G pseudotyped virus (data not shown). (B) Ti
exhibited strong reactivity to GST-gp41-30.plasma samples neutralized viruses pseudotyped with VSV-G
(data not shown), indicating specific, antibody-mediated neu-
tralization of HIV-1.
Based on neutralization assays against four HIV-1 isolates,
CWRU-4 exhibited the broadest and the most potent neutraliz-
ing activity. To determine further the extent of its breadth,
neutralization assays were performed against 24 virus isolates,
including sixteen from clade B, four from clade C, and four
from clade A. As shown in Table 1, plasma samples from pa-
tient CWRU-4 were able to neutralize all of the viruses tested,
albeit at different potency. Some isolates such as MN and
SF162.LS are historically easily neutralizable “Tier 1” viruses
(Mascola et al., 2005), whereas other viruses from a Standard
Reference Panel of Subtype B HIV-1 Env Clones (NIH ARRRP
Cat no. 11227) and Subtype A and C designed for Tier 2 and 3
studies are considered neither unusually sensitive nor resistant
to neutralization. Based on our past experience (D. Montefiori),
very few patient samples have this level of breadth and potency
of neutralizing activity. At present, the epitope(s) targeted by
these neutralizing antibodies are not known.
Identification of immunogenic linear epitopes within the
C-terminal half of gp41 ectodomain
Despite the lack of absolute correlation between antibody
reactivity against GST-gp41-30 and breadth or potency of neu-
tralizing activity on an individual patient basis, the fact that four of
six patients (CWRU-3, -4, -5 and -6) with the highest reactivity
against the protein exhibited strong neutralizing activity sug-
gested that something might be unique about these patients. Toses (BAL, AD8, DH12 and 89.6) were used to assess neutralizing activity in a
absence of plasma. (A) Twelve patients identified as having either high or low
b b12 (12.5 μg/ml) and uninfected patient (HIV-ve) were used as controls. None
tration analyses of neutralizing activity of plasma samples from six patients who
Table 1
Neutralizing activity of plasma samples from patient CWRU-4
Virus Clade ID50 Virus Clade ID50 Virus Clade ID50
MN B 7103 TRO.11 B 828 Du156.12 C 511
Bal.26 B 1093 AC10.0.29 B 912 Du172.17 C 969
SF162.LS B 43,740 RHPA4259.7 B 1,229 ZM197M.PB7 C 176
SS1196.1 B 807 THRO4156.18 B 311 CAP210.2.00.E8 C 175
6535.3 B 1091 REJO4541.67 B 1,517 Q842.d12 A 139
QH0692.42 B 129 TRJO4551.58 B 262 Q168.a2 A 216
SC422661.8 B 144 WITO4160.33 B 60 Q461.e2 A 37
PVO.4 B 457 CAAN5342.A2 B 215 Q769.d22 A 181
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munogenic linear epitopes were examined by ELISA using 30
overlapping peptides (15-mers, 11 a.a. overlap) spanning amino
acid residues 572 through 702 (numbering based on MCON6;
569–699 on HxB2).
Out of 30 peptides, three were recognized strongly by all
six patients (Fig. 6A). Two peptides (596–610: LGIWGCSGK-Fig. 6. Identification of immunogenic linear epitopes targeted by patients using overla
exhibited the strongest reactivity against GST-gp41-30 were further analyzed by pepti
the top and the key regions are indicated, including the binding sites of caveolin-1, 2F
et al., 1996). Aligned amino acid sequences of peptides that are immunoreactive are s
mAbs 2F5 and 4E10 are indicated in red and blue, respectively (see panel C). (B) Plasm
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL) and HR2 (C34: WMEW
shows average reactivity of six patients in either high or low GST-gp41-30-reactive gr
to 2F5 (1 μg/ml) and 4E10 (20 μg/ml).LICTTT, and 600–614:GCSGKLICTTTVPWN)werewithin the
immunodominant domain of cluster I (designated a.a. 579–604
on HxB2: RVLAVERYLKDQQLLGIWGCSGKLIC; (Binley
et al., 1996)). Since both peptides exhibited very similar anti-
body reactivity profile, the core epitope likely consist of residues
GCSGKLICTTT, which contains both cysteine residues pre-
viously reported to be critical for recognition (Gnann et al., 1987).pping peptide ELISA. (A) Plasma samples (1:100 dilution) from six patients that
de ELISA (20 pmol/well). A schematic diagram of a section of gp41 is shown on
5 and 4E10, and three immunogenic clusters as defined by Binley et al. (Binley
hown. Peptides are numbered based on MCON6 envelope. Those recognized by
a samples were further evaluated with larger peptides encompassing HR1 (N36:
DREINN-YTSLIHSLIEESQNQQEKNEQELL), and 5-helix bundle. The plot
oups. MAb 98-6 was used as a positive control. (C) Immunoreactivity of peptides
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two immunodominant peptides in cluster I were also reactive,
but only for certain patient plasma: 580–594 (CWRU-3), 584–
598 and 588–602 (CWRU-4, -5 and -6), 592–606 (CWRU-3
and -5), and 604–618 (CWRU-3, -4 and -5). It is interesting to
note that these peptides are recognized only by patient plasma
that exhibit broader, more potent neutralizing activity. That is,
patients CWRU-1 and -2 did not mount detectable antibodies
against epitopes within these peptides. It has been shown that
antibodies that target the immunodominant epitopes do not
neutralize HIV-1. It remains to be determined whether any of the
antibodies that bind to epitopes adjacent to these immunodomi-
nant epitopes have neutralizing activity or not.
The third highly immunoreactive peptide (656–670: QEKNE-
QELLALDKWA) was found in a region that overlaps cluster II
(designated a.a. 644–663 on HxB2: RLIEESQNQQEKNEQEL-
LAL; (Binley et al., 1996)). This peptide contains residues
“ALDKWA”, which is the core epitope for mAb 2F5 (ELDKWA)
(Muster et al., 1993) and not considered to be a part of cluster II
(Binley et al., 1996; Goudsmit et al., 1990). The fact that a peptide
just upstream of it (652–666: SQNQQEKNEQELLAL) is rec-
ognized by none of the patient plasma indicates critical par-
ticipation of and/or contribution from residues “DKWA” in
forming the correct conformation of epitope(s) within the peptide.
This is interesting for two reasons. Firstly, most patients (i.e. all
except CWRU-2) also recognized a peptide just downstream of it
(660–674: EQELLALDKWASLWN). Secondly, direct ELISA
analyseswith 2F5 showed that the antibody binds to both peptides
656–670 and 660–674 (Fig. 6C). Therefore, we believe some of
these patients may have mounted antibodies similar to 2F5 in
epitope recognition, if not neutralizing activity, during natural
infection.
One of the most striking findings of this study was that
antibodies from patient CWRU-6 bound strongly to peptides
672–686 (LWNWFDITNWLWYIK) and 680–694 (NWLWYI-
KIFIMIVGG) (Fig. 6A), the same two peptides recognized by
mAb 4E10 (Fig. 6C). Although 4E10 binds primarily to residues
“NWFDIT”, the antibody is known to also interactwith sequences
downstream of it (e.g. L682 and W683; L679 and W680 for
HxB2; (Brunel et al., 2006)). This strongly suggests, although
does not prove, that CWRU-6 may have mounted 4E10-like
antibodies. Moreover, antibodies from patient CWRU-6 bound
strongly to peptide 664–678 (LALDKWASLWNWFDI), which
contains epitopes recognized by both 2F5 and 4E10 in almost
complete entirety. In this regard, the antibody that recognizes this
peptide might have Z13-like properties, a Fab fragment that has
been shown to bind to an epitope overlapping residues of both
2F5 and 4E10 epitopes (Nelson et al., 2007; Zwick et al., 2001).
Another interesting observation is that antibodies from patient
CWRU-4, which exhibited themost potent and broad neutralizing
activity, strongly reacted with peptide 624–638 (EIWDNMTW-
MEWEREI). This peptide encompasses a motif highly homo-
logous to caveolin-1-binding domain (WNNMTWMEW).
Caveolin-1 is a scaffolding protein that organizes and concen-
trates specific ligands within the caveolae membranes. The
caveolin-1 binding site has recently been shown to play an im-
portant role during the formation of a fusion pore or endocytosisof HIV-1 (Huang et al., 2007). What draws our interest is the
finding that rabbits immunized with a peptide encompassing
the caveolin-1 binding domain (SLEQIWNNMTWMQWDK)
mounted quite broad neutralizing activity against multiple pri-
mary HIV-1 isolates from different clades (Hovanessian et al.,
2004). Therefore, one possible source of broadly neutralizing
activity for patient CWRU-4 is antibodies directed against the
caveolin-1 binding domain.
As shown in Fig. 4, antibody reactivity against GST-gp41-64
was significantly greater than that against GST-gp41-30 for most
patients. This was the case even for the six patients with the
highest reactivity against GST-gp41-30, except for CWRU-2 and
-6, who showed similar reactivity. However, ELISA analyses
using 15 a.a. peptides revealed almost no antibody reactivity
against those in C-terminal 64 residues upstream of the MPER
(i.e. a.a. 623–656; Fig. 6A). Antibody reactivitywas not observed
even when much longer 34 a.a. peptide was used (C34), which
encompasses the entire HR2 domain (Fig. 6B, second panel).
These results indicate that antibodies that specifically recognize
GST-gp41-64 most likely bind to highly conformational and/or
non-contiguous epitopes, which are formed only in the presence
of the C-terminal 30 residues (i.e. MPER). This interpretation is
consistent with a previous study, which reported that antibodies
directed against cluster III (a.a. 617–646; 614–643 for HxB2) are
highly conformational (Binley et al., 1996). Although none of the
12 patients (6 high- and 6 low-reactivity against GST-gp41-30)
we analyzed mounted detectable antibody responses against
either N36 or C34 peptides corresponding to HR1 and HR2
regions, respectively (Fig. 6B, first and second panel), all of them
showed equally strong reactivity against a 5-helix bundle protein
complex (Fig. 6B, third panel), a monomeric polypeptide
consisting of three HR1 and two HR2 segments connected by
linker sequences designed to mimic a trimeric, HR1-HR2 coiled-
coil structure (Root et al., 2001). This strong response is likely a
result of antibodies against non-functional, trimeric gp41 stumps
on the surface of virions exposed after gp120 shedding (Moore
et al., 2006). As expected, mAb 98-6 recognized 5-helix bundle,
but not N36 or C34 peptides (Fig. 6B, fourth panel).
ELISA results (Fig. 6A) revealed that plasma samples from
some of the patients exhibited peptide reactivity profiles that
resembled those of 2F5 or 4E10 antibodies (i.e. recognition of
peptides 656–670 and 660–674 by 2F5, and peptides 672–686
and 680–694 by 4E10). Considering that some of these patients
might indeed have 2F5- or 4E10-like antibodies, we were curious
as to the prevalence of patient antisera that exhibit similar profiles.
We conducted ELISA analyses of all 44 patient samples simul-
taneously (except for CWRU-5 due to insufficient amount) using
eight peptides that span the entire MPER. Two peptides from the
cluster I immunodominant domain (596–610 and 600–614) were
also evaluated, and an unrelated peptide (SARS-CoV spike gly-
coprotein a.a. 61–76) was used as a negative control.
Although the two immunodominant peptides were highly
reactive for most individuals, about one fourth of the patients
mounted surprisingly weak antibody responses against the
region (A450 values less than 0.5; Fig. 7). In general, antibody
reactivity against peptide 656–670 correlated with that against
GST-gp41-30. However, there were several notable exceptions
Fig. 7. Identification of immunogenic linear epitopes in gp41 by ELISA usingM group consensus peptides. Immunoreactivity of plasma samples from 43 patients were
analyzed against seven peptides from cluster I region (a.a. 580–618), eight peptides from the MPER (a.a. 656–698), and one peptide encompassing the caveolin-1-
binding site (a.a. 624–638). A negative control peptide derived from SARS-CoV S protein showed antibody reactivity profile similar to peptides 684–698 (data not
shown). CWRU-5 was not included due to insufficient amount of the sample. Peptides recognized by mAbs 2F5 and 4E10 are indicated. Patient samples that reacted
significantly against both peptides recognized by 2F5 or 4E10 (arbitrarily defined as A450 value greater than twice the sum of average and standard deviation of SARS
peptide background reactivity) are indicated by triangles or dots, respectively. It should be noted that y-axis for seven peptides from the MPER are in different scale.
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CWRU-8, -16, -18, -19 and -20). Plasma samples from eight
patients (indicated by triangles) reacted substantially above
background levels for both peptides 656–760 and 660–674,
suggesting these patients might have mounted 2F5-like
antibodies. All but one of these patients had fairly strong anti-
body reactivity against GST-gp41-30. Plasma from several pa-
tients reacted substantially to peptide 664–678 (e.g. patients
CWRU-3, -6, -8, -9, -17 and -26), suggesting that they might
have Z13-like antibodies (Nelson et al., 2007; Zwick et al.,
2001). Finally, plasma from four patients (CWRU-3, -6, -11 and
-12) reacted against peptides 672–686 and 680–694, which are
recognized by 4E10. Very weak or near background levels of
antibody reactivity were observed for peptides 668–682, 676–
690, and 684–698. Together, these results suggest that several
patients develop antibodies against epitopes that are near, or
overlap with, those targeted by 2F5 or 4E10.Discussion
In view of the limited number of BR-Nabs that have been
identified to date, better characterization of antibody responses in
HIV-1-infected patients and identification of new and potent BR-
Nabs is critical in designing vaccine immunogens. As a first step in
our efforts toward achieving these goals, we have systematically
generated and purified five soluble fusion proteins containing the
C-terminal 30, 64, 100, 142 or 172 amino acids of gp41 ectodomain
from anM group consensus sequence. These recombinant proteins
appear to have intact antigenic structures based on immunoprobing
analyses with BR-Nabs 2F5 and 4E10, 98-6, and antisera from
HIV-1-infected patients. Characterization of antibody responses
against gp41 had been largely limited to short peptides because the
protein has been difficult to produce in soluble forms. Therefore,
the set of gp41 fragments we have generated will be invaluable
reagents for characterizing antibody responses against HIV-1 gp41.
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results in misfolding and aggregation of proteins, which ac-
cumulate in inclusion bodies. Our gp41 protein fragments were
no exception despite the fact that they were fused to GST.
However, we were successful in denaturing the proteins, re-
folding, and renaturing them into soluble forms in the absence of
any detergent, although we experienced greater difficulties in
solubilizing the two larger fragments and obtained substantially
lower yields. Although we did not attempt to express gp41
protein fragments without GST, we are quite certain that GST
played a critical role in allowing the proteins to renature into
soluble forms. This conclusion is based in part from our ob-
servation that attempts to remove GST by cleaving between the
two fusion partners with thrombin resulted in immediate
precipitation of gp41 (data not shown). We speculate that GST
could be functioning in a way analogous to gp120 by masking
some of the hydrophobic patches on gp41 away from aqueous
solvent to prevent non-specific aggregation.
Since GST-gp41 fusion proteins are antigenically intact,
shown by their ability to bind not only BR-Nabs 4E10 and 2F5,
but also conformational antibodies that bind to cluster III, they
could be potential candidates for vaccine development. How-
ever, these proteins are not ideal as antigens for a vaccine as the
large GST portion is likely to be immunodominant over smaller
gp41 fragments. On the other hand, these proteins are highly
suitable for structural studies, especially GST-gp41-64 since it is
well recognized by both 2F5 and 4E10 and we can easily
produce up to 40 mg of the protein from 1 L of bacterial culture.
To date, the only solved crystal structures of gp41 are HR1/HR2
coiled-coil core and peptide epitopes that bind to 2F5 and 4E10
(Cardoso et al., 2005; Chan et al., 1997; Ofek et al., 2004; Tan
et al., 1997; Weissenhorn et al., 1997b). Determining the
structure of the entire MPER with the HR2 domain would
facilitate better understanding of gp41 function and designing
antigens that can elicit antibodies such as 2F5 or 4E10.
All five GST-gp41 fusion proteins were equally well
recognized by 2F5, indicating that the epitope is conformationally
identical and similarly exposed amongst all proteins (Fig. 3A).
Although all five proteins were also recognized by 4E10, GST-
gp41-100 and -30 were about 5- and 20-fold less reactive, re-
spectively, when compared to the other three proteins (Fig. 3B).
This result was somewhat unexpected taking into account that the
4E10 epitope is considered to be linear and is only four amino
acids downstream of the 2F5 epitope. One likely explanation is
that although the epitope is linear, it is highly conformational,
requiring other regions of gp41 for proper formation of the anti-
genic epitope structure. In this regard, it has previously been
reported that the 4E10 epitope assumes a helical conformation
(Cardoso et al., 2005) and modifications that enhance helical
properties increase antibody-binding affinity (Brunel et al., 2006;
Cardoso et al., 2007). Based on these findings, our current
hypotheses are (1) sequences within GST-gp41-64 upstream of
the MPER (i.e. between C-terminal residues 64 and 30) provide
constraints on the helical conformation of 4E10 epitope, thereby
enhancing antibody binding compared to GST-gp41-30; (2) ad-
ditional sequences between HR1 and HR2 within GST-gp41-100
are either disrupting or masking the epitope partially to reduce4E10 binding; and (3) this inhibition is reversed when the HR2
domain forms coiled-coil structure with HR1, as demonstrated by
reactivity to mAb 98-6 (Fig. 3C), in GST-gp41-142 and -172.
More detailed biochemical and structural analyses are needed to
test these hypotheses.
We observed tremendous variation in antibody responses to
gp41 amongst different patients, not only with respect to the
magnitude, but also the pattern of antibody reactivity against
different gp41 fragments and peptides. One parameter that could
affect the magnitude of antibody responses is plasma viral load.
Greater antigenic stimulation might be expected to induce
stronger antibody responses. In this regard, the duration of in-
fection since seroconversion and possible treatment of patients
with anti-retroviral therapy could potentially influence antibody
levels (Binley et al., 2000; Lafeuillade et al., 1997; Morris et al.,
2001). An important contribution may also stem from the overall
responsiveness of the patients' immune system to antigenic
stimulation; higher viral load could also mean greater deteriora-
tion of helper T cell immunity, and therefore weaker B cell re-
sponse. In the present study, the patients were chosen randomly,
without considerations to these parameters, because we were
primarily interested in studying differential epitope targeting in
individual patients and identifying those who mounted strong
antibody responses against potential neutralization epitopes (viz.
MPER).
The variation in antibody responses against different gp41
regions or peptides in different patients could be attributable to
differences in patients' immune system (e.g. immunoglobulin
gene repertoire) and/or HIV-1 isolates the patients are infected
with (e.g. envelope protein sequence). We saw that many patients
who mounted strong antibody responses against the MPER (i.e.
reactivity against GST-gp41-30) exhibited broader, more potent
neutralizing activity compared to those who did not. It should
be emphasized, however, that we presently do not know the
epitope(s) targeted by Nabs. They could be directed against the
MPER, other regions of gp41, or epitopes within gp120. Further-
more, the breadth of neutralizing activity could be polyclonal with
multiple Nabs targeting different epitopes. In any event, further
characterization of B cell repertoire, virus isolates from these
patients, and mAbs generated from the patients could provide
clues as to how BR-Nabs could be elicited.
Considering that plasma samples from four of six patients that
showed strong antibody reactivity against GST-gp41-30 had
potent neutralizing activity, this fusion protein could be used as a
tool for rapidly screening patient sera to identify those who
might have BR-Nabs. In this regard, we were somewhat dis-
appointed with the fact that patients CWRU-1 and -2, whose
antisera reacted most strongly against the protein, did not exhibit
potent neutralizing activity as we had hoped. One possible
explanation is that there might be epitopes in the MPER that
elicit non-neutralizing antibodies. It is conceivable that these
antibodies could prevent binding of Nabs that target epitopes in
close proximity due to steric hindrance (e.g. 2F5 or 4E10). In this
case, observed neutralizing activity would be determined by
relative antibody titers and affinity between neutralizing and
non-neutralizing antibodies that compete for the adjacent
epitopes. If this hypothesis is true, then it would have strong
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have to have correct neutralization epitopes, the antigen should
not have competing non-neutralizing epitopes nearby.
Attempts to elicit antibodies with similar properties to 2F5
and 4E10 in animals immunized with antigens containing the
gp41 MPER have not been successful. It has been proposed that
this difficulty is due to autoantigen mimicry by HIV-1 based on
observations that 2F5 and 4E10 cross-react with phospholipid
cardiolipin (Alam et al., 2007; Haynes et al., 2005; Sanchez-
Martinez et al., 2006). This view that 2F5 and 4E10 have
properties of autoantibodies is quite controversial since they
have been used in passive immunization studies without any
complication (Ferrantelli et al., 2004; Joos et al., 2006; Trkola
et al., 2005). In addition, a more recently published study
reports that 2F5 fails to exhibit any cardiolipin reactivity under
their set of experimental conditions (Scherer et al., 2007). Also,
while 4E10 does have general affinity to lipids, this reactivity
resembles that of anti-phospholipid antibodies elicited during
many infections rather than that of autoimmune antiphospholipid
syndrome. Thus, the inability to elicit antibodies with similar
properties to 2F5 and 4E10 might not be attributable to immune
tolerance mechanisms. In this study, we have identified many
patients who mounted antibodies against the same peptides
recognized by 2F5 and, to a lesser extent, by 4E10 (Fig. 7).
Although we have yet to determine the precise epitopes and
specificities of these antibodies, the results of our study suggest
that patients who mount antibodies against epitopes that are near,
or overlap with, those targeted by 2F5 or 4E10 may not be as rare
as has previously been thought. In agreement with our findings,
Gray et al. (Gray et al., 2007) have recently reported up to one
third of HIV-1-infected patients mount Nabs against the MPER.
Additional studies with a larger panel of patient samples and
detailed biochemical analyses of purified antibodies that target the
MPER could provide more definitive answers. In this regard, the
fusion proteins we generated could be ideal reagents for rapid
assessment of antibody responses against gp41 and for affinity
purification of MPER-directed antibodies.
Materials and methods
Cloning GST-gp41 fusion constructs
To generate plasmid constructs expressing five GST-gp41
fusion proteins, regions encoding C-terminal 30, 64, 100, 142 or
172 amino acids of M group consensus gp41 ectodomain were
PCR-amplified from pcDNA-MCON6gp160 (kindly provided
by Dr. Beatrice Hahn, University of Alabama; (Gao et al.,
2005)). PCR reactions were carried out using a common reverse
primer 5′-GAATTCTTAATGGTGATGATGGTGATGCTT-
GATGTACCA-CAGCCAGTTGG-3′ for all five constructs,
and individual forward primers, 5′-CGCGGATCCGAGAA-
GAACGAGCAGGAGC-3′ (for -30); 5′-CGCGGATCCGAC-




-172). Underlined and double underlined sequences indicate re-striction enzyme sites BamHI and EcoRI, respectively. Amplified
DNA fragments were digested with BamHI and EcoRI and
ligated into corresponding sites on vector pGEX-2T (GE Health-
care Life Sciences). GST-gp41-64 contains inadvertent, incon-
sequential I649V mutation (numbering based on MCON6).
Protein expression and purification
E. coli BL21(DE3) was transformed with recombinant plas-
mid or pGEX-2T and cultured overnight at 37 °C in superbroth
containing ampicillin (50 μg/ml). Cells were diluted 1:100 in
fresh superbroth and cultured to 0.6 OD600 at 37 °C, at which
time fusion protein expression was induced with 1 mM IPTG
(isopropyl-beta-D-thiogalactopyranoside) for 2 h. Cells were
harvested, washed and lysed in PBS (phosphate-buffered saline)
by sonication. The cell lysate was subjected to centrifugation at
10,000 rpm (HB4 rotor) for 20 min in a Sorvall Superspeed
centrifuge. Pellets containing inclusion bodies were washed
with PBS and solubilized in PBS containing 8 M urea. Insoluble
debris was removed by centrifugation and soluble proteins were
bound to Ni-NTA resin (QIAGEN) on a column. GST-gp41-30,
-64 and -100 were renatured through serial incubations with 10
bed volumes of PBS containing a decreasing step gradient of
urea at 8 M, 6 M, 4 M, 3 M, 2 M, 1 M and 0 M. Renaturation of
GST-gp41-142 and -172 fusion proteins required much slower,
continuous gradient of reduction in urea concentration, particu-
larly below 4M. The process typically took place over the period
of 2–3 days. The column was washed with PBS containing
20 mM imidazole and proteins were eluted in PBS containing
200 mM of imidazole. The eluted proteins were dialyzed against
PBS, concentrations were determined by Bradford assay, and
purity was assessed by SDS-PAGE followed by silver staining.
Non-fusion GST was expressed similarly. To purify the pro-
tein, cells were lysed in PBS by sonication and the lysate was
subjected to centrifugation at 5000 rpm (HB4 rotor) for 30 min.
GST was purified according to the manufacturer's protocol
(Novagen). Briefly, GST·Bind™ Resin was added to the super-
natant and incubated at 4 °C for 60 min. GST-bound resin was
pelleted by centrifugation, washed twice with PBS, loaded onto
a column, and washed again with GST Binding/Wash buffer
(4.3 mM Na2HPO4, 1.47 mM KH2PO4, 0.137 M NaCl, 2.7 mM
KCl, pH 7.3). GSTwas eluted in a buffer (50 mM Tris–HCl, pH
8.0) containing 10 mM reduced glutathione. The eluted proteins
were dialyzed against PBS, and concentrations were determined
by a Bradford assay.
Immunoprecipitation and Western blot
HIV-1 gp41 mAbs 2F5 (Buchacher et al., 1994; Purtscher
et al., 1996, 1994) and 4E10 (Stiegler et al., 2001) were
obtained from Dr. Hermann Katinger through the NIH AIDS
Research and Reference Reagent Program (NIH ARRRP).
Immunoprecipitation (IP) was done by incubating GST or GST-
gp41 fusion proteins with either 2F5 or 4E10 and protein A
agarose in IP buffer (10 mM Tris, pH 7.5, 200 mM NaCl, 1 mM
EDTA, 0.5% Triton X-100). The mixture was agitated overnight
at 4 °C. Subsequently, antigen–antibody complex bound to
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Proteins were denatured and eluted from the resin by heating in
boiling water for 3 min in 2× SDS-PAGE sample buffer. Im-
munoprecipitated or purified proteins were subjected to SDS-
PAGE (10% acrylamide), followed by Western blot analyses
using rabbit anti-GST IgG (Molecular Probes) and goat anti-
rabbit IgG conjugated horseradish peroxidase (Pierce). Protein
bands were visualized with SuperSignal chemiluminescent
substrates (Pierce) according to the manufacturer's protocol.
ELISA
Plasma samples from 44 HIV-1-infected patients were
obtained through the Case Western Reserve University Center
for AIDS Research Clinical Core. Samples were heat in-
activated at 56 °C for 30 min. prior to use. 6-helix and 5-helix
bundle proteins (Root et al., 2001) were kindly provided by
Dr. Michael Root of Thomas Jefferson University. The fol-
lowing reagents were obtained through the NIH ARRRP: HIV-
Ig from NABI and NHLBL; HIV-1 M group consensus enve-
lope overlapping peptides (Cat #9487), HIV-1 IIIB N36 and C34
Peptides ((Gallo et al., 2004); Cat #9822 and 9824, respectively)
from DAIDS; mAb 98-6 (Gorny et al., 1989; Robinson et al.,
1991; Tyler et al., 1990; Xu et al., 1991) from Dr. Susan Zolla-
Pazner. SARS-CoV S protein peptide (PFYSNVTGFH-
TINHTF; Cat #9605) was obtained through the NIH Biodefense
and Emerging Infections Research Resources Repository.
Purified GST-gp41 fusion proteins or overlapping peptides
(0.5 or 20 pmol per well, respectively) were coated onto 96-well
Nunc-Immuno Plates (Nunc; Cat #439454) using antigen coating
buffer (150 mM Na2CO3, 350 mM NaHCO3, 30 mM NaN3, pH
9.6) at 4 °C overnight. N36, C34, 5-Helix and 6-Helix antigens
were coated at 33 ng/well. Wells were blocked with PBS (pH 7.5)
containing 2.5% skim milk and 25% FBS at 37 °C for 1 h, then
washed four times with 0.1%Tween 20 in PBS. NP-40was added
to patient plasma samples (0.1% final) before dilution in blocking
buffer. Antibodies and plasma samples were diluted as indicated,
added to wells and incubated for 2 h at 37 °C in 200 μl blocking
buffer. Wells were washed 4 times, and secondary antibody goat
anti-human IgG conjugated to horseradish peroxidase (Pierce; Cat
#31410) was incubated at 1:3000 dilution at 37 °C for 1 h. Wells
were washed 4 times, and developed by adding 100 μl TMB
HRP-substrate (Bio-Rad) for 5–10 min. Reactions were stopped
with 50 μl of 2 N H2SO4. Plates were read on a microplate reader
(Versamax by Molecular Devices) at 450 nm. Experiments were
done in duplicates.
Neutralization assays
Single round infection assays in TZM-bl cells (Derdeyn et al.,
2000; Platt et al., 1998; Wei et al., 2002) using pseudoviruses
were performed as we and others have previously described
(Derdeyn et al., 2000; Kim et al., 2001; Wei et al., 2002, 2003).
Assays were done in two laboratories with slightly different
protocols. In Cho lab, pseudoviruses were generated using
pNL4-3.Luc.R-E- (Connor et al., 1995; He et al., 1995), pCMV-
Tat (Jeang et al., 1987), and pLTR-gp140 constructs encodinggp140 of HIV-1 isolates BAL, 89.6, DH-12, and AD8 (Kim
et al., 2001) or pHCMV-G encoding VSV-G protein (Burns et
al., 1993). Briefly, 3×107 293Tcells at 85% confluency in T225
flask were co-transfected by calcium phosphate method with
150 μg pNL4-3Luc.R-E-, 150 μg pLTR-gp140 or pHCMV-G
constructs, and 25 μg pCMV-Tat. Transfected cells were
incubated for 16 h before replacing medium. Cells were cultured
for two more days, at which time culture medium was collected
and clarified by centrifugation. Cell-free virus stocks were ali-
quoted and stored at −80 °C. Pseudoviruses were titered in
TZM-bl cells by β-galactosidase staining as previously de-
scribed (Kim et al., 2001; Wei et al., 2002). All cells were
cultured at 37 °C, 5% CO2, in DMEM supplemented with 10%
FBS, penicillin/streptomycin, and glutamine.
Heat-inactivated plasma samples or mAbs diluted in serum-
free DMEM at indicated concentrations were mixed with about
100–150 infectious units of pseudoviruses. The mixture was
incubated at 37 °C for 1 h, and then added to TZM-bl target cells
in 96-well plates in 50 μl. After 1 h adsorption, the virus
inoculum was removed and 200 μl of fresh medium was added.
Two days post infection, cells were lysed and virus infectivity
was determined using β-Glo luminescence assay as per manu-
facturer's protocol (Promega). Relative luminescence units
(RLU) were measured using a luminometer (Bio-Rad). Assays
were performed in duplicates or in quadruplicates. Uninfected
TZM-bl cells were used to determine background luminescence
and mean background was subtracted from all readings. Virus
infectivity was determined as a %age of no-serum controls (i.e.
virus only).
In Montefiori lab, assays were also done in TZM-bl cells as
described (Li et al., 2005; Montefiori, 2004). Briefly, 200
TCID50 of virus was incubated with serial 3-fold dilutions of
serum sample in triplicate in a total volume of 150 μl for 1 hr at
37 °C in 96-well flat-bottom culture plates. Freshly trypsinized
cells (10,000 cells in 100 μl of growth medium containing
75 μg/ml DEAE dextran) were added to each well. One set of
control wells received cells + virus (virus control) and another
set received cells only (background control). After a 48-h in-
cubation, 100 μl of cells was transferred to 96-well black solid
plates (Costar) for measurements of luminescence using the
Britelite Luminescence Reporter Gene Assay System (Perki-
nElmer Life Sciences). Assay stocks of Env-pseudotyped vi-
ruses were prepared by transfection in 293T cells and were
titrated in TZM-bl cells as described (Li et al., 2005).
Statistical analyses
For the purpose of comparing high and low GST-gp41-30-
binding patient groups for the breadth of neutralizing activity,
summary % infectivity for individual patients was calculated as
the average % infectivity observed for each individual across the
four viruses. These statistically independent summary values of
% infectivity were then used to compare groups using both the
two group t-test and the non-parametric Wilcoxon Rank Sum
Test. Observed % neutralization of all four viruses was sig-
nificantly higher ( pb0.01) in the high GST-gp41-30 antibody
binding group for both tests.
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